CLINICAL TRIALS PROFILE FOR CUTIVATE
✉ Email this page to a colleague
All Clinical Trials for CUTIVATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00119158 ↗ | Combination Therapy for Atopic Dermatitis | Completed | Novartis Pharmaceuticals | Phase 4 | 2004-10-01 | Atopic dermatitis is a chronic relapsing disease with acute flares. The standard therapy is to treat acute flares using topical medications. The two most common classes of topical medications for atopic dermatitis (AD) are topical corticosteroids and topical calcineurin inhibitors. Pimecrolimus and topical corticosteroids exert their activity by different mechanisms, there may be a synergistic effect of the combination therapy. Therefore, a combination therapy may provide a faster resolution of severe skin lesions and consequently reduce the duration of the topical corticosteroid treatment. Another benefit of the combination therapy maybe the use of a lower potency corticosteroid to achieve the same degree of clearance. The hypothesis of this trial is that the combination of the two agents will lead to faster clearance than the single agent of topical corticosteroids. |
| NCT00119158 ↗ | Combination Therapy for Atopic Dermatitis | Completed | Children's Hospital of Philadelphia | Phase 4 | 2004-10-01 | Atopic dermatitis is a chronic relapsing disease with acute flares. The standard therapy is to treat acute flares using topical medications. The two most common classes of topical medications for atopic dermatitis (AD) are topical corticosteroids and topical calcineurin inhibitors. Pimecrolimus and topical corticosteroids exert their activity by different mechanisms, there may be a synergistic effect of the combination therapy. Therefore, a combination therapy may provide a faster resolution of severe skin lesions and consequently reduce the duration of the topical corticosteroid treatment. Another benefit of the combination therapy maybe the use of a lower potency corticosteroid to achieve the same degree of clearance. The hypothesis of this trial is that the combination of the two agents will lead to faster clearance than the single agent of topical corticosteroids. |
| NCT00546000 ↗ | Cutivate Lotion HPA Axis Pediatric Study | Completed | Fougera Pharmaceuticals Inc. | Phase 4 | 2007-07-01 | A multi-center, open-label, Phase IV, unblinded study using Cutivate (fluticasone propionate, 0.05%)lotion and it's possible effects on the HPA axis of infants diagnosed with atopic dermatitis. |
| NCT00763529 ↗ | Elocon vs Fluticasone in Localized Psoriasis (P03197) | Completed | Merck Sharp & Dohme Corp. | Phase 4 | 2003-01-01 | This is an open-label, randomized, parallel-group clinical study. The primary objective is to assess the difference in response rate between mometasone furoate cream 0.1% (once daily) vs fluticasone propionate cream 0.05% (twice daily) by the end of Day 4 and Day 8 in the management of Indian patients with localized psoriasis. |
| NCT00763529 ↗ | Elocon vs Fluticasone in Localized Psoriasis (P03197) | Completed | Schering-Plough | Phase 4 | 2003-01-01 | This is an open-label, randomized, parallel-group clinical study. The primary objective is to assess the difference in response rate between mometasone furoate cream 0.1% (once daily) vs fluticasone propionate cream 0.05% (twice daily) by the end of Day 4 and Day 8 in the management of Indian patients with localized psoriasis. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CUTIVATE
Condition Name
Clinical Trial Locations for CUTIVATE
Trials by Country
Clinical Trial Progress for CUTIVATE
Clinical Trial Phase
Clinical Trial Sponsors for CUTIVATE
Sponsor Name
